Another phase III clinical study, SASCIA (NCT04595565), randomized patients with HER2- breast cancer with residual disease after neoadjuvant chemotherapy (NACT) to SG or treatment of physician’s choice (TPC), is also ongoing. Here, ERBB2 is linked to breast carcinoma.